Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe …
…, SW Gerritz, FJ Schoenen, CJ Thomas, J Aubé
Index: Coombs, Thomas C.; Tanega, Cordelle; Shen, Min; Wang, Jenna L.; Auld, Douglas S.; Gerritz, Samuel W.; Schoenen, Frank J.; Thomas, Craig J.; Aube, Jeffrey Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 12 p. 3654 - 3661
Full Text: HTML
Citation Number: 19
Abstract
Substituted pyrimidine inhibitors of the Clk and Dyrk kinases have been developed, exploring structure–activity relationships around four different chemotypes. The most potent compounds have low-nanomolar inhibitory activity against Clk1, Clk2, Clk4, Dyrk1A and Dyrk1B. Kinome scans with 442 kinases using agents representing three of the chemotypes show these inhibitors to be highly selective for the Clk and Dyrk families. Further off-target ...
Related Articles:
[Mohamed, Tarek; Zhao, Xiaobei; Habib, Lila K.; Yang, Jerry; Rao, Praveen P.N. Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 7 p. 2269 - 2281]
Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity
[Chen, Kuen-Feng; Pao, Kuan-Chuan; Su, Jung-Chen; Chou, Yi-Chieh; Liu, Chun-Yu; Chen, Hui-Ju; Huang, Jui-Wen; Kim, Inki; Shiau, Chung-Wai Bioorganic and Medicinal Chemistry, 2012 , vol. 20, # 20 p. 6144 - 6153]